John Ayrton
London, ENG WC2A1AP, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat.
Journal: The Journal of antimicrobial chemotherapy
Published: September 18, 2025
In vitro and clinical data demonstrate negligible risk of drug-drug interactions with opelconazole, a novel inhaled antifungal agent.
Journal: The Journal of antimicrobial chemotherapy
Published: March 20, 2025
Beyond GLP-1s: The blueprint for systemic therapeutics that will reshape aging and medicine.
Journal: British journal of clinical pharmacology
Published: March 02, 2025
Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in Aspergillus fumigatus infected mice: Pulmonary PK-PD analysis of anti-fungal PC945.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 13, 2020
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent.
Journal: Pharmacology research & perspectives
Published: September 28, 2020
Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
Journal: British journal of pharmacology
Published: September 26, 2017
Voriconazole Concentrations in Plasma and Epithelial Lining Fluid after Inhalation and Oral Treatment.
Journal: Basic & clinical pharmacology & toxicology
Published: March 22, 2017
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 03, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026